Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2019.101909
Abstract: OBJECTIVE This meta-analysis investigated the effectiveness of PARP inhibitors (PARPis) as maintenance treatment in platinum sensitive recurrent ovarian cancer (ROC), stratifying results based on BRCA mutational status into five different categories: whole population, germ-line BRCA… read more here.
Keywords: maintenance treatment; brca mutational; analysis; treatment platinum ... See more keywords
Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2018.10.023
Abstract: Epithelial ovarian cancer (EOC) is the leading cause of death due to gynecologic malignancy. The majority of advanced stage EOC patients, even those who respond well to frontline therapy, will ultimately recur and succumb to… read more here.
Keywords: eoc; treatment; review; platinum sensitive ... See more keywords
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2018.1513793
Abstract: ABSTRACT Background: The challenges of managing relapsed ovarian cancer increase as more advanced lines of chemotherapy are achieved. Methods: A case study is presented to illustrate the complexities of selecting treatment in a patient with… read more here.
Keywords: platinum; relapsed ovarian; treatment; ovarian cancer ... See more keywords
The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1325871
Abstract: ABSTRACT Introduction: Recurrence is a common event in endothelial ovarian cancer (EOC) patients, and the choice of the most appropriate treatment is driven by the platinum-free interval, molecular characteristics of the disease such as BRCA… read more here.
Keywords: parp inhibitors; agents parp; ovarian cancer; antiangiogenic agents ... See more keywords
Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz250.017
Abstract: Abstract Background Randomised phase 3 trials have demonstrated that poly (ADP-ribose) polymerase (PARP) inhibitors significantly improve progression-free survival in BRCA-mutant high-grade serous and endometrioid ovarian carcinoma. Consequently, the demand for germline and tumour BRCA1/2testing has… read more here.
Keywords: brca1 2testing; brca1; tumour brca1; cancer ... See more keywords
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Sign Up to like & getrecommendations! Published in 2019 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000794
Abstract: Debulking surgery, followed by taxane/platinum-based chemotherapy has traditionally been the first-line treatment for advanced ovarian cancer. However, most patients will experience recurrence afterwards, and receive subsequent lines of therapy. It has been proposed that extending… read more here.
Keywords: ovarian cancer; treatment; cancer; platinum based ... See more keywords
Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Obstetrics and Gynaecology Research"
DOI: 10.1111/jog.15184
Abstract: Several years have passed since olaparib maintenance therapy was approved in patients with platinum sensitive recurrent ovarian cancer (PSROC). We speculated that the response to platinum‐based chemotherapy (PBC) would be impaired at the time of… read more here.
Keywords: platinum; platinum sensitive; olaparib maintenance; maintenance therapy ... See more keywords
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-000623
Abstract: Objective To report results from an integrated efficacy and safety analysis supporting the European Commission's approval of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy treatment for relapsed, platinum-sensitive, BRCA-mutated ovarian cancer. Methods Efficacy was analyzed… read more here.
Keywords: treatment; safety; rucaparib; ovarian cancer ... See more keywords
Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003993
Abstract: Objective Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to in vitro data, BRCA mutated patients are sensitive to replicative stress agents but BRCA status is… read more here.
Keywords: carboplatin; platinum sensitive; relapse; brca status ... See more keywords
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835919849753
Abstract: Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to… read more here.
Keywords: parp inhibitors; treatment; sensitive relapsed; ovarian cancer ... See more keywords
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.02745
Abstract: PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial… read more here.
Keywords: chemotherapy; sensitive relapsed; ovarian cancer; chemotherapy patients ... See more keywords